Completed PHASE1 NCT00002248
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients
Sponsor: Univax Biologics Inc
Conditions
Cryptosporidiosis HIV Infections
Interventions
Cryptosporidium Immune Whey Protein Concentrate (Bovine)
Updated 5 times since 2017 Last updated: Jun 23, 2005
A PHASE1 clinical study on Cryptosporidiosis and HIV Infections, this trial is completed. The trial is conducted by Univax Biologics Inc and has accumulated 5 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Univax Biologics Inc
Data source: NIH AIDS Clinical Trials Information Service
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Atlanta, United States
- • Boston, United States
- • Los Angeles, United States
- • New York, United States
- • San Francisco, United States